IGF-1 LR3
A modified IGF-1 analogue, not the approved mecasermin product.
Investigational / no FDA-approved-treatment claim
A modified IGF-1 analogue, not the approved mecasermin product.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proponents claim IGF-1 LR3 may promote muscle growth and tissue repair.
The review separates pharmacologic signaling from limited direct human efficacy evidence. This analogue must not inherit mecasermin approval or dosing.
Evidence and source limits
The source linked here describes research or investigational use. It does not establish an FDA-approved indication for this compound or for a research-chemical product. A claimed use is not an established benefit.
Product identity, purity, route, safety and suitability remain separate questions. Research-purpose-only labeling does not authorize human use. This note provides no dosing, preparation or purchase guidance.
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.